OUR PEOPLE

Thomas P. Reeves | President and CEO
Thomas P. Reeves joined Interface Biologics in November of 2008 as President and Chief Executive Officer. Tom brings a wealth of experience in running different companies in a variety of industries through various stages of growth. Most recently, he was President and COO of Occulogix, Inc. (NASDAQ: OCCX) a medical device company where he was instrumental in their Initial Public Offering raising over $100 million. Prior to OccuLogix, Mr. Reeves was the President of Borderfree, an international e-commerce service provider which was sold to Canada Post in 2004. Mr Reeves has also led Beamscope Canada Inc., Merisel Canada, Merisel Europe, and Merisel’s UK operation. Mr. Reeves started his career with the Boston Consulting Group (BCG) in San Francisco. He holds a BA in Economics, magna cum laude, from Harvard University and an MA in International Relations from the Australian National University.

 

 

 

 

 

 
Dr. Peng Chen, Ph. D. | Quality Assurance Manager/ Analytical Lab Manager
Dr. Chen has 14 years of experience in academia, chemical/medical device companies, and entrepreneurship before joining Interface Biologics. He taught undergraduate chemistry at Hubei University in China, worked for GE Plastics as a Senior Chemist and for Integra LifeSciences as a Senior Researcher in the United States. He also started a company in Canada to test innovative technologies. Peng has a BS in Chemistry from Wuhan University, a MS in Organic Chemistry from University of Louisville, and a Ph.D. in Analytical Chemistry from Indiana University.
Bunmi Dosunmu, Vice President, Finance
Bunmi comes to Interface Biologics Inc. with 15 years experience in finance, corporate and operational management and provides effective direction and leadership in areas of treasury and financial management, business planning, cost control, IT and administration. Bunmi worked as a Finance Consultant with UCB Pharma Canada Inc. and was responsible for setting up the finance and accounting function of the company. Prior to UCB, Bunmi was the Controller of OccuLogix Inc. and was involved in the Company’s Initial Public Offering in December 2004 which raised over $100 million. Bunmi is a Chartered Accountant, a Certified Public Accountant and holds a B.Sc in Accounting from the University of Ilorin, Nigeria.
Dr. Roseita Esfand, Ph. D. | Director, Research & Development
Dr. Esfand has been a member of staff at Interface Biologics since September, 2003, leading the Kinesyx development team. Prior to joining Interface Biologics, Roseita spent over seven years at DNT Inc. (USA), where she developed a variety of technologies in polymer drug delivery, focusing on viral and cancer therapy. She worked closely with regulatory authorities for submission and approval of novel polymeric systems. Her experience in developing technologies led to her transfer to PanBio Ltd. (Australia), for replacing traditional gold visualization techniques with novel polymers in the diagnostic area. Roseita was also assigned to Starpharma Ltd. (Australia), working on polyvalent polymers as nanotechnology platforms for viral and cancer therapy. She was successful in transferring technologies to both companies. Roseita is a member of the executive team of the CIC, a coalition of scientists that develops and advocates public policy positions on scientific issues. Roseita has a Ph.D in Pharmaceutical Sciences from the University of Kent, UK. Prior to leaving the United Kingdom she spent time working at SmithKline Beecham.
Jeannette Ho, M.A.Sc. | Director of Operations
Ms. Ho is a charter member of the Interface Biologics scientific team. During her tenure, she has served as Director of Research and Development, Quality Assurance Manager and currently leads the Endexo™ development team. Jeanette was involved in developing Endexo™ technology during her graduate studies at University of Toronto. At that time, she was also President and CEO of Jycho Surface Technologies, Inc., the company that began the scale-up and commercialization of the Endexo™ technology. She brings expertise in surface modifying macro-molecule (SMM) technology, polymer development and characterization, industrial processing and device manufacturing. Jeanette holds a B.A.Sc. in Chemical Engineering from Waterloo University and an M.A.Sc. from University of Toronto.

 

 

 

 

 
Dr. Sanjoy Mullick, Ph. D. | Senior Scientist
Dr. Mullick joined Interface Biologics in November 2005, bringing with him over 8 years of experience in biomaterials and polymers for medical devices and biopharmaceuticals. Prior to joining Interface Biologics, Sanjoy worked at Dabur Pharma, Dabur Research Foundation, in India, where he was a senior polymer scientist working on the development of biopolymers for nano-particle and microsphere-based polymer drug delivery platforms for anti-cancer and other drug therapies. He has broad experience in diverse fields and has worked in Singapore, India, United States and Canada. Sanjoy earned his B.S. (Chemistry Majors, Physics, Math minor) and Bachelor of Technology (Plastics and Rubber Technology), from University of Calcutta, India; his Ph.D. from Utah State University, and has held Post Doctoral Positions at Brigham Young University in Provo, Utah and at Queen’s University in Kingston, Ontario.
Dr. Paul Santerre, Ph.D. | Chief Scientific Officer
Dr. Santerre founded Interface Biologics Inc. in 2001 to develop improved medical implants based on his innovative research in polymer chemistry. Dr. Santerre is responsible for the strategic direction of research and development at Interface. Previously, Dr. Santerre was the manager of the materials development laboratory at the University of Ottawa and developed technology for the Ottawa Heart Institute artificial heart (World Heart Corporation). He is currently a full professor of biomaterials with appointments at the Faculty of Dentistry and the Institute for Biomaterials and Biomedical Engineering at the University of Toronto. He is an expert in the areas of physical, surface and biological characterization of polymers, polymer synthesis, material biocompatibility, drug polymers, and medical device manufacturing.
Frank Shannon, Vice President, Clinical & Regulatory Affairs
Mr. Shannon joined Interface Biologics in March 2009 bringing more than 17 years of clinical development, regulatory and medical marketing experience in the international pharmaceutical, medical device and contract research industries. He has led the design, execution, analysis, and reporting of numerous clinical programs and outcomes research studies, including several clinical registries and disease management programs with industry, government and NGOs. Prior to Interface Biologics, Frank was at i3 Innovus, an international CRO, where he led operations for late phase research in Canada and clinical registry programs, globally.  Previously, he has held various national and global positions in clinical, regulatory and/or outcomes research at Occulogix, Inc., Boehringer Ingelheim, Hoffmann – La Roche, Genentech and Ciba-Geigy. He brings a wealth of experience in the therapeutic areas of infectious diseases, urology, nephrology, endocrinology, oncology, ophthalmology, neurovascular, and cardiovascular medicine, and continues his research, in the latter, at the University of Toronto.
Mark Steedman, Vice President, Business Development
Mark coordinated the formation of the company in December 2001. He negotiated licensing terms with the University of Toronto, prepared the terms of the seed capital funding, and organized the company for operations beginning in January 2002. Mark is responsible for managing the financing and business aspects of the corporation. He raised $12M in seed capital for the corporation. He has taken the staff of Interface from 0 to 15 people and helped recruit the senior management team. Mr. Steedman was instrumental in landing early deals with several large medical device manufacturers, and oversaw company operations from early R&D to its first revenues in 2004. Mark holds degrees in Applied Science in Engineering, a Bachelor of Arts in Biology both from Queen’s University and an MBA from Wilfrid Laurier University.